Cargando…

Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role

OBJECTIVE: This study aimed to identify the association between duration of HU administration prior to IM treatment and MMR achievement in chronic-phase CML while evaluating the role of MDA, HIF-1α and P-gp. METHODS: The study was conducted at Dr. Cipto Mangunkusumo National General Hospital and Dha...

Descripción completa

Detalles Bibliográficos
Autores principales: Rinaldi, Ikhwan, Reksodiputro, Ary Harryanto, Jusman, Sri Widia, Harahap, Alida, Setiabudy, Rianto, Wanandi, Septelia Inawati, Tambunan, Karmel, Suharti, Catharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173389/
https://www.ncbi.nlm.nih.gov/pubmed/31870110
http://dx.doi.org/10.31557/APJCP.2019.20.12.3689
_version_ 1783524441559400448
author Rinaldi, Ikhwan
Reksodiputro, Ary Harryanto
Jusman, Sri Widia
Harahap, Alida
Setiabudy, Rianto
Wanandi, Septelia Inawati
Tambunan, Karmel
Suharti, Catharina
author_facet Rinaldi, Ikhwan
Reksodiputro, Ary Harryanto
Jusman, Sri Widia
Harahap, Alida
Setiabudy, Rianto
Wanandi, Septelia Inawati
Tambunan, Karmel
Suharti, Catharina
author_sort Rinaldi, Ikhwan
collection PubMed
description OBJECTIVE: This study aimed to identify the association between duration of HU administration prior to IM treatment and MMR achievement in chronic-phase CML while evaluating the role of MDA, HIF-1α and P-gp. METHODS: The study was conducted at Dr. Cipto Mangunkusumo National General Hospital and Dharmais Cancer Hospital, Jakarta using retrospective cohort design to analyse the association between the duration of HU before IM and its MMR achievement and cross-sectional design to analyse the association between MDA, HIF-1α and P-gp expressions with MMR achievement. Main subjects were chronic-phase CML patients treated by HU prior to IM for ≥ 12 months and HU only. The subjects were divided into four main groups: (1) chronic-phase CML patients treated with HU ≤ 6 months + IM ≥ 12 months and (2) HU > 6 months + IM ≥ 12 months (3) HU only (≤ 6 months), (4) HU only ( >6 months). Subjects were obtained from January 2015 to May 2016. Data were gathered through history taking, physical examination, medical record evaluation, and blood sample analysis. Bivariate analysis was conducted using chi square, independent T-test, and Mann-Whitney according to the variables. RESULTS: Administration of HU for more than 6 months prior to IM was associated with unsuccessful MMR achievement (RR 1.60; 95%CI 1.29-2.00). MDA level, HIF-1α, P-glycoprotein expression were not associated with MMR achievement but the mean MDA level (0.63±0.31 vs 0.75±0.41 p=0.461) and median P-glycoprotein expressions {16,92 (0,04 – 43,86) vs. 5,15 (0,02–39,64); p=0.311} were found to be higher in patients receiving HU for > 6 months group than in HU ≤ 6 months group consecutively. CONCLUSION: Administration of HU for more than 6 months prior to IM was associated with unsuccessful MMR achievement in chronic-phase CML. The study suggested that P-glycoprotein overexpression as the predictor for unsuccessful MMR achievement.
format Online
Article
Text
id pubmed-7173389
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-71733892020-05-01 Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role Rinaldi, Ikhwan Reksodiputro, Ary Harryanto Jusman, Sri Widia Harahap, Alida Setiabudy, Rianto Wanandi, Septelia Inawati Tambunan, Karmel Suharti, Catharina Asian Pac J Cancer Prev Research Article OBJECTIVE: This study aimed to identify the association between duration of HU administration prior to IM treatment and MMR achievement in chronic-phase CML while evaluating the role of MDA, HIF-1α and P-gp. METHODS: The study was conducted at Dr. Cipto Mangunkusumo National General Hospital and Dharmais Cancer Hospital, Jakarta using retrospective cohort design to analyse the association between the duration of HU before IM and its MMR achievement and cross-sectional design to analyse the association between MDA, HIF-1α and P-gp expressions with MMR achievement. Main subjects were chronic-phase CML patients treated by HU prior to IM for ≥ 12 months and HU only. The subjects were divided into four main groups: (1) chronic-phase CML patients treated with HU ≤ 6 months + IM ≥ 12 months and (2) HU > 6 months + IM ≥ 12 months (3) HU only (≤ 6 months), (4) HU only ( >6 months). Subjects were obtained from January 2015 to May 2016. Data were gathered through history taking, physical examination, medical record evaluation, and blood sample analysis. Bivariate analysis was conducted using chi square, independent T-test, and Mann-Whitney according to the variables. RESULTS: Administration of HU for more than 6 months prior to IM was associated with unsuccessful MMR achievement (RR 1.60; 95%CI 1.29-2.00). MDA level, HIF-1α, P-glycoprotein expression were not associated with MMR achievement but the mean MDA level (0.63±0.31 vs 0.75±0.41 p=0.461) and median P-glycoprotein expressions {16,92 (0,04 – 43,86) vs. 5,15 (0,02–39,64); p=0.311} were found to be higher in patients receiving HU for > 6 months group than in HU ≤ 6 months group consecutively. CONCLUSION: Administration of HU for more than 6 months prior to IM was associated with unsuccessful MMR achievement in chronic-phase CML. The study suggested that P-glycoprotein overexpression as the predictor for unsuccessful MMR achievement. West Asia Organization for Cancer Prevention 2019 /pmc/articles/PMC7173389/ /pubmed/31870110 http://dx.doi.org/10.31557/APJCP.2019.20.12.3689 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Rinaldi, Ikhwan
Reksodiputro, Ary Harryanto
Jusman, Sri Widia
Harahap, Alida
Setiabudy, Rianto
Wanandi, Septelia Inawati
Tambunan, Karmel
Suharti, Catharina
Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role
title Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role
title_full Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role
title_fullStr Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role
title_full_unstemmed Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role
title_short Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role
title_sort longer hydroxyurea administration prior to imatinib mesylate is risk factor for unsuccessful major molecular response in chronic-phase chronic myeloid leukemia: possibility of p-glycoprotein role
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173389/
https://www.ncbi.nlm.nih.gov/pubmed/31870110
http://dx.doi.org/10.31557/APJCP.2019.20.12.3689
work_keys_str_mv AT rinaldiikhwan longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole
AT reksodiputroaryharryanto longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole
AT jusmansriwidia longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole
AT harahapalida longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole
AT setiabudyrianto longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole
AT wanandisepteliainawati longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole
AT tambunankarmel longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole
AT suharticatharina longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole